{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Peripheral Neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Hypophosphatemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Peripheral Edema"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Rash"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Dysgeusia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hyperglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Depression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Psychiatric Disorder, other"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Generalized Muscle Weakness"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"A summary of the number of participants with grade 3 or higher treatment related adverse events for adverse events that had an overall incidence of greater than 15% (any grade) as assessed by Common Terminology Criteria for Adverse Events (CTCAE 4).","groups":[{"description":"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)\n\nConsolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15\n\nLenalidomide\n\nBortezomib\n\nDexamethasone","id":"OG000","title":"Treatment Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With Grade 3 or Higher Treatment Related Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}